ABSTRACT To determine whether prophylactic antiarrhythmic therapy influences mortality in highrisk patients after acute myocardial infarction, 143 such patients were randomized in a double-blind individually dose-adjusted, placebo-controlled trial an average of 14 + 7 days after myocardial infarction and followed for 1 year. Patients were judged to be at high risk on the basis of (1) ejection fraction less than 40% (n = 60), (2) arrhythmias of Lown class 3 or higher (n = 26), or (3) both (n = 57). Aprindine was chosen because of its long half-life, few side effects, and antiarrhythmic efficacy. Baseline characteristics in the treatment arms did not differ. Holter-detected arrhythmias were reduced in aprindine-treated patients at 3 months (p < .001) and at 1 year (p < .001). One patient was lost to follow-up; in the remaining patients 1 year mortality was 20% (28/142; 12 aprindine and 16 placebo). There was no significant difference between the two study arms in overall mortality and sudden death. However, among those who died, median duration of survival was longer in aprindine-treated patients (86 vs 21.5 days) (p = .04). Although antiarrhythmic treatment with aprindine of high-risk patients after myocardial infarction does not affect 1 year survival, mortality appears to be delayed; thus there may be a role for short-term treatment before more definitive therapy such as surgery. Circulation 75, No. 4, 792-799, 1987. SUDDEN DEATH after hospital discharge following myocardial infarction is thought to be caused by malignant ventricular arrhythmias,l and patients with highgrade arrhythmias in the late hospital phase after myocardial infarction have an increased risk of sudden death after hospital discharge.2`7 Membrane-active antiarrhythmic agents reduce the frequency of ventricular arrhythmias in patients with acute and chronic coronary heart disease,8 and these agents have been studied in patients at risk of sudden death after myocardial infarction.9 10 To date, however, no study has shown convincingly that the prophylactic use of antiarrhythFrom the Francis
SUDDEN DEATH after hospital discharge following myocardial infarction is thought to be caused by malignant ventricular arrhythmias,l and patients with highgrade arrhythmias in the late hospital phase after myocardial infarction have an increased risk of sudden death after hospital discharge.2`7 Membrane-active antiarrhythmic agents reduce the frequency of ventricular arrhythmias in patients with acute and chronic coronary heart disease,8 and these agents have been studied in patients at risk of sudden death after myocardial infarction.9 10 To date, however, no study has shown convincingly that the prophylactic use of antiarrhyth-mic agents can influence survival after hospital discharge in high-risk survivors of myocardial infarction. 10 This report describes a 1 year, randomized, doubleblinded, individually dose-adjusted, placebo-controlled trial to determine whether the administration of a membrane-active antiarrhythmic agent, aprindine, " influences survival in high-risk survivors of acute myocardial infarction. Aprindine, a tertiary amine with properties similar to those of quinidine and procainamide, 1 " was chosen as the test drug because it has several major advantages as a prophylactic agent against sudden death after myocardial infarction: (1) it is highly effective against serious ischemia-related arrhythmias; (2) it has a long half-life and predictable pharmacokinetics and may be taken on a twice-daily dosing schedule; (3) the most common side effects, including tremor, nervousness, dizziness and memory impairment, are dose related and readily reversible with dosage titration; and (4) major side effects, agran-THERAPY AND PREVENTION-SUDDEN DEATH ulocytosis and cholestatic jaundice, are relatively uncommon and reversible upon discontinuation of the drug.
Methods
Population. Between January 1980 and January 1984, patients admitted to the Francis Scott Key Medical Center (formerly the Baltimore City Hospitals) or The Johns Hopkins Hospital within 48 hr of the onset of symptoms of acute myocardial infarction were eligible to be considered for the study. Acute myocardial infarction was defined by the presence of the following: (1) anginal chest, arm, or neck pain lasting longer than 20 min, (2) new Q waves of 0.04 sec or greater duration or new T wave inversion lasting greater than 1 week, and (3) creatine kinase rise to greater than normal.
Inclusion criteria. Eligible patients were invited to participate in the study if they met the following criteria: (1) arrhythmias at 1 week after myocardial infarction of Lown class 3, 4a, or 4b'2 on a 24 hr Holter monitor, or ejection fraction at 1 week after myocardial infarction of less than 40% as determined by cardiac gated blood pool scan, or both high-grade arrhythmias and low ejection fraction; (2) ability and willingness of the patient to give informed consent; and (3) permission of the patient's physician. The study protocol was approved by the institutional committee on human research.
Lown class 3 arrhythmias, i.e., multifocal premature ventricular beats (VPBs), were defined as at least 24 VPBs in 24 hr, 12 each of two different forms, or 12 of one form and a total of 12 of up to 12 other forms. Lown class 4a arrhythmias, i.e., couplets, were defined as at least 12 couplets in 24 hr. Lown class 4b arrhythmias, i.e., ventricular tachycardia, was defined as at least three VPBs in a row at 120 beats/min or greater. Radionuclide ejection fraction was determined in the left anterior oblique view that gave the best separation between the right and left ventricles and was calculated by standard computerized techniques. 13 Exclusion criteria. Patients were ineligible for the study if they had (1) symptomatic VPBs or ventricular tachycardia with 10 beats or more in a row; (2) persistent second-or third-degree heart block; (3) advanced life-threatening diseases of other organ systems, such as uremia, advanced respiratory disease, cancer or liver failure; (4) complications such as stroke or thromboembolism that required prolonged hospitalization; (5) previously documented hypersensitivity or intolerance to aprindine; or if they (6) were previously treated with membraneactive antiarrhythmic agents such as quinidine, procainamide, or phenytoin; (7) Administration of study drug. After informed consent had been obtained, patients were assigned in double-blinded, randomized fashion to receive aprindine or placebo. Numbered lots of large capsules (25 mg of aprindine/placebo) or small capsules (10 mg of aprindine/placebo) were supplied. A loading dose of 200 mg of aprindine or placebo was given in four divided doses 6 hr apart. If no side effects were noted, the patient was instructed to take two large capsules (50 mg of aprindine/placebo) every 12 hr. The choice of loading and initial maintenance doses was based on previous experience with aprindine at our institution and at other institutions,`, 14, 15 which had demonstrated therapeutically effective drug levels in this dosage range. Patients were identified, enrolled, and randomized as soon as possible after the performance and analysis of the initial qualifying 24 hr Holter monitoring and gated blood pool scan, and treatment commenced within 12 hr after consent was given. Before discharge, complete blood counts and liver function tests were obtained. The study drug was to be continued for 1 year after discharge from hospital.
Blinding. The physician investigators, patients, and nursing personnel were blinded to the drug assignment. Drug assignments were known to the statistical consultant and to the technician who measured and reported the drug levels.
One patient who developed severe muscle weakness was thought to have a progressive neuromuscular disorder and the study drug was discontinued; the drug assignment, aprindine, was reported by the statistical consultant to the consulting neurologist. The investigators remained blinded throughout the study, including the study drug dosage adjustment period and the follow-up period (see below).
Individual dosage adjustment of study drug. All patients were seen weekly during the first 16 weeks after randomization to adjust study drug dosage and to monitor for neutropenia, one of the major side effects of aprindine,16 which occurs most often during the first 4 months of therapy. "' 16 Predose blood levels were obtained at each visit and reported by the reference laboratory as a percentage of maximum predicted therapeutic dose. The dose of the drug was adjusted by the investigators until drug levels were at 75% of the predicted maximum dose,'4 at which time a repeat 24 hr Holter electrocardiogram was obtained. Patients in the placebo treatment arm were handled in the same fashion, except that sham levels were reported by the reference laboratory in a pattern that was similar to that seen in patients in the aprindine treatment arm. If Lown class 3, 4a, or 4b arrhythmias were noted in an asymptomatic patient, the drug dose was adjusted upward. Minor complaints compatible with drug intolerance, including tremors, dizziness, and gastrointestinal complaints, were treated by adjusting the level of the study drug or by administering treatment to relieve symptoms. After the initial 16 week period the patient was seen at 3 month intervals, at which time the patient's clinical status was assessed and a 12 lead electrocardiogram, study drug blood levels, liver function tests, complete blood and platelet counts, and a 24 hr Holter electrocardiogram were obtained. The study drug was discontinued for hypersensitivity reaction, persistent toxic symptoms despite reported levels of the agent below 75% of the maximum therapeutic level, neutropenia, or thrombycytopenia. The Mortality. There was no significant difference between treatment arms for total deaths (p = .31) or sudden deaths (p = .09) (figure 1). However, among patients who died from all causes, the median duration of survival was longer in the aprindine-treated patients (86 days) than in the placebo-treated patients (21.5 days) (p = .04). Fifty percent (8/16) of all deaths among patients in the placebo treatment arm occurred by day 18 after randomization, whereas the first death in a patient in the aprindine treatment arm occurred on day 29 in a patient recovering from bypass surgery several days after the drug had been discontinued. The pattern of deaths by month after randomization shows a significant difference in mortality during the first month, when only 8% (1/12) of all deaths in the aprindine arm occurred compared with 56% (9/16) of all deaths in the placebo arm (p = .02).
When the data are censored so that only patients who were actively taking the study drug are considered, there is also no significant difference between treatment arms in mortality at 1 year. Among patients who died of all causes, the median duration of survival was longer among patients in the aprindine arm (64 days) than in the placebo arm (8.5 days) (p < .05); the first death in a patient actively taking aprindine occurred on day 47 after randomization.
There was no difference in mortality within the subgroups of both treatment arns that entered the study with an ejection fraction less than 40%, with arrhythmias of Lown class 3 or greater, or with both ( THERAPY AND PREVENTION-SUDDEN DEATH tricular fibrillation in patients within a few hours of the onset of acute myocardial infarction.'0 22 However, no clinical trial of the use of membrane-active antiarrhythmic agents in high-risk patients after acute myocardial infarction has shown a beneficial effect on mortality. Of the seven large randomized trials including more than 100 patients, none showed a beneficial effect on mortality and several showed a trend toward a detrimental effect.23-29 In the most recently reported large randomized trial of the use of mexiletine, a membrane-active antiarrhythmic agent, in high-risk patients after acute myocardial infarction with 1 year follow-up,29 no early or late benefit was seen. There was a trend toward an increased mortality in the intervention arm despite effective suppression of arrhythmias.
Our study was designed to determine whether the membrane-active antiarrhythmic agent, aprindine, a highly effective drug with a long half-life and properties similar to those of procainamide and quinidine, ' l15 would reduce the risk of death in high-risk survivors of acute myocardial infarction. Our study differed from previously reported studies of this question in several important features: (1) High-risk patients were selected. Mortality from all causes in the placebo arm of other studies ranged from only 4.8%27 at 1 year to 11.6% at 6 months.25 Mortality in the placebo arm of our study was 22% (16/72) at 1 year and 18% at 6 months. In no other reported study was ejection fraction evaluated routinely, whereas in our study all patients had their ejection fraction determined by gated blood pool scanning and 85% (121/143) of patients had an ejection fraction less than 40%. (2) Study drug dose was individually adjusted. No other double-blinded study individually adjusted the dose of the study drug so that blood levels were in a range known to be effective in reducing sudden death. The pharmacokinetics of aprindine are predictable and the levels we achieved with a twice-daily dosing schedule have been shown to be effective in improving survival in a sample of patients with ventricular tachycardia or fibrillation. 14 (3) A drug highly effective against lethal ventricular arrhythmias was used. Aprindine is highly effective against lethal ventricular arrhythmias and has been shown to be effective in a group of patients with symptomatic ventricular tachycardia or fibrillation in improving the proportion of patients remaining alive and asymptomatic. 14 It appears to be among the most effective drugs available for treatment of lethal ventricular arrhythmias.9
Although some previously reported studies of the prophylactic use of membrane-active antiarrhythmic agents in survivors of acute myocardial infarction have been criticized because high-grade arrhythmias were not one of the criteria for enrollment,'0 an ejection fraction of less than 40% after acute myocardial infarction has repeatedly been shown to be a major risk factor for death after discharge from hospital; most of these patients die suddenly.30 31 Malignant ventricular arrhythmias are thought to be the cause of death in most of these patients, 1 perhaps because extensive scar or ventricular aneurysm may form an anatomic substrate responsible for the generation of malignant arrhythmias by creating reentry circuits, or may extend the vulnerable period when an ectopic beat with a critical amplitude and timing may trigger ventricular fibrillation.32 In the canine preparation,33 sustained monomorphic ventricular tachycardia can be induced reproducibly by electrical stimulation 2 weeks after experimental myocardial infarction and the likelihood of inducibility is strongly correlated with the size of the infarct. Among our patients enrolled because of an ejection fraction under 40%, without high-grade arrhythmias, the prevalence of high-grade arrhythmias increased over time, and this increase was greatest in the placebo-treated patients. By the time the first follow-up 24 hr ambulatory electrocardiogram was performed, half the deaths in the placebo arm had already occurred. Thus an ejection fraction of less than 40% after myocardial infarction identifies a group of patients who are likely to manifest high-grade arrhythmias on follow-up examinations. Marked natural variability in frequency of arrhythmias has been noted previously by other investigators,34 and an increase in frequency and complexity of ventricular ectopic beats in the first 1 to 6 months after acute myocardial infarction has been shown. 3'35 Our study indicates that over a 1 year period the prophylactic administration of an effective membraneactive antiarrhythmic agent, aprindine, given in a randomized, double-blind, individually dose-adjusted, placebo-controlled trial to high-risk survivors of acute myocardial infarction appears to reduce mortality in the first month after randomization and may prolong survival by approximately 2 months in those patients who later die; however, mortality at 1 year does not appear to be affected. This apparent reduction in early mortality appears to be due in large part to the difference in the incidence of early sudden death between the two groups: half of the deaths (8/16) in the placebo arm occurred by day 18 after randomization and seven of these were sudden. The first death among the aprindine-treated patients did not occur until day 29; this was a patient who died suddenly after bypass surgery several days after withdrawal of the drug. The first death in a patient actively taking aprindine did not occur until day 47 after randomization. Fifty percent of deaths in the aprindine arm occurred by day 65, and only two of six were sudden.
Although more aprindine-treated patients underwent coronary artery bypass graft surgery (11 aprindine vs five placebo; see table 3), this difference was not significant (p = .51). The first bypass graft surgery performed on an aprindine-treated patient was at 17 days after randomization; at that time, seven deaths (six of them sudden) had already occurred in the placebo group. To control for the possibility that differences in clinical outcome after coronary bypass graft surgery may have accounted for the apparent differences in mortality between the aprindine and placebo treatment arms, we reanalyzed the data, censoring the data at the time of bypass graft surgery. The results of this censored analysis show no difference between the two treatment arms in death from all causes at 365 days (p = .22) or at 120 days (p -.10). However, the censored analysis does show a significant difference between the two treatment arms in mortality due to sudden death: when the data are censored, among patients who did not undergo bypass graft surgery there are four sudden deaths in the aprindine arm and 11 sudden deaths in the placebo arm. There is a significant difference in mortality due to sudden death at 1 year (p = .048, Breslow's test) and at 120 days (p = .027, Breslow's test). It is possible that some of the placebotreated patients who died suddenly soon after randomization may have been candidates for coronary artery bypass surgery had they survived for several more weeks.
The suggested decrease in mortality in the aprindine treatment arm during the first month after randomization is noteworthy. It has been shown that mortality is highest in the first few months after myocardial infarction1-' 5, 7. 36-38 and then progressively decreases.2 Moss et al. 3 showed that frequent ventricular ectopic beats were associated with increased mortality only during the first 4 months after myocardial infarction. It thus seems reasonable to expect that the greatest benefit of antiarrhythmic therapy would be seen in the first few months after myocardial infarction. This has not been demonstrated, however, in prior studies of prophylactic antiarrhythmic therapy after myocardial infarction. Many studies have enrolled patients after myocardial infarction for a variable period of time, approaching 2 months in some.10 39 This is beyond the period of highest mortality, and thus the power to demonstrate a difference between treatment arms may be reduced. This is in contrast to trials of the prophylactic use of X3-blocking agents. In the Norwegian multicenter trial of timolol after myocardial infarction, a progressively increasing difference in mortality due to cardiac death was seen throughout the study follow-up period.'"
The difference in mortality from all causes at 1 year between the aprindine arm and the placebo arm (17% vs 22%) was small, and the statistical power to detect a significant difference is limited by the sample size. To show a significant difference between treatment arms for death from all causes with p < .05 and a beta error of 20%, more than 1000 such high-risk patients in each treatment arm would have been necessary. 19 The characteristics of an ideal antiarrhythmic agent for prophylactic use against sudden death after discharge of survivors of acute myocardial infarction include high efficacy in suppressing ventricular arrhythmias, a long half-life, and tolerable side effects.9 At the time this study was initiated, aprindine appeared to be one of the most promising agents available. In our study, the drug appeared to be an effective antiarrhythmic agent with tolerable side effects. Although central nervous system side effects, usually weakness and tremor, were seen in 15% of patients treated with aprindine, they were usually controlled by reducing the dose Only one case of significant neutropenia was seen and this promptly resolved when the drug was discontinued. The long half-life of the drug allowed it to be taken on a convenient 12 hr dosing schedule and compliance was good. No suggestion of exacerbation of ventricular arrhythmias was seen despite high drug levels achieved in some patients. The prolongation of survival associated with aprindine treatment in this study cannot necessarily be extrapolated without qualification to the use of other antiarrhythmic agents. The primary advantage of aprindine may be its long halflife and the relative ease with which therapeutic drug levels with tolerable side effects may be achieved.14 Aprindine may have other properties that make it particularly effective in reducing sudden death in patients in the early postinfarction period.
Finally, it has been demonstrated that patients with depressed ejection fraction and triple-vessel disease benefit from bypass surgery. 41 It is among this group of patients, however, that the highest early mortality is seen. ' 
